121 related articles for article (PubMed ID: 37924648)
1. Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies.
Schina A; Pedersen S; Spenning AL; Laursen OK; Pedersen C; Haslund CA; Schmidt H; Bastholt L; Svane IM; Ellebaek E; Donia M
Eur J Cancer; 2023 Dec; 195():113392. PubMed ID: 37924648
[TBL] [Abstract][Full Text] [Related]
2. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
Donia M; Kimper-Karl ML; Høyer KL; Bastholt L; Schmidt H; Svane IM
Eur J Cancer; 2017 Mar; 74():89-95. PubMed ID: 28335891
[TBL] [Abstract][Full Text] [Related]
6. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
7. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.
Zhao J; Li D; Xie S; Deng X; Wen X; Li J; Wu Z; Yang X; Li M; Tang Y; Zhang X; Ding Y
Front Immunol; 2022; 13():1083840. PubMed ID: 36618343
[TBL] [Abstract][Full Text] [Related]
8. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
9. External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities.
Sørensen MS; Gerds TA; Hindsø K; Petersen MM
Clin Orthop Relat Res; 2018 Aug; 476(8):1591-1599. PubMed ID: 30020148
[TBL] [Abstract][Full Text] [Related]
10. The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients.
Ellebaek E; Svane IM; Schmidt H; Haslund CA; Donia M; Hoejberg L; Ruhlmann C; Guldbrandt LM; Køhler UH; Bastholt L
Cancer Epidemiol; 2021 Aug; 73():101943. PubMed ID: 33962356
[TBL] [Abstract][Full Text] [Related]
11. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
12. Does the SORG Machine-learning Algorithm for Extremity Metastases Generalize to a Contemporary Cohort of Patients? Temporal Validation From 2016 to 2020.
de Groot TM; Ramsey D; Groot OQ; Fourman M; Karhade AV; Twining PK; Berner EA; Fenn BP; Collins AK; Raskin K; Lozano S; Newman E; Ferrone M; Doornberg JN; Schwab JH
Clin Orthop Relat Res; 2023 Dec; 481(12):2419-2430. PubMed ID: 37229565
[TBL] [Abstract][Full Text] [Related]
13. Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada.
O'Sullivan DE; Boyne DJ; Gogna P; Brenner DR; Cheung WY
Curr Oncol; 2023 Apr; 30(4):4166-4176. PubMed ID: 37185430
[TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
15. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
[TBL] [Abstract][Full Text] [Related]
19. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
Hanna TP; Nguyen P; Baetz T; Booth CM; Eisenhauer E
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):609-617. PubMed ID: 30196844
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]